Intermediate for Afatinib. Afatinib (trade name: Gilotrif) is an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2) for the treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC). Afatinib has been approved by the U.S Food and Drug Administration on July 12, 2013.
Specifications
Product Name: N-(3-Chloro-4-fluorophenyl)-6-nitro-7-(phenylsulfonyl)quinazolin-4-amine
Synonyms: N/A
CAS Number: 945553-94-6
Molecular Weight:  458.8506
Molecular Formula:  C20H12ClFN4O4S
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.
SMILES: [O-][N+](=O)c1cc2c(ncnc2cc1S(=O)(=O)c1ccccc1)Nc1ccc(c(c1)Cl)F